Daxor
  • About Daxor
    • Company Overview
    • Executive Team
    • Board of Directors
    • Careers
    • Contact Us
  • The BVA-100
    • Importance Of Blood Volume Measurement
    • Blood Volume Measurement Test
    • Principle Of Blood Volume Measurement
    • Performing Blood Volume Measurement
    • Blood Volume Measurement Report
    • Resources
    • FAQ’s
  • Healthcare Professionals
    • COVID-19
    • Heart Failure
    • Critical Care
    • Other Indications
    • Clinical Evidence
    • Case Studies
    • The BVA Brief Newsletter
    • Reimbursement
    • Technical Resources
    • Clinical Support Team
  • Innovations
  • Investors
    • Tear Sheet
    • Press Releases
    • Executive Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • SEC Filings
    • FAQ’s
    • Key Contacts
  • Contact
  • About Daxor
    • Company Overview
    • Executive Team
    • Board of Directors
    • Careers
    • Contact Us
  • The BVA-100
    • Importance Of Blood Volume Measurement
    • Blood Volume Measurement Test
    • Principle Of Blood Volume Measurement
    • Performing Blood Volume Measurement
    • Blood Volume Measurement Report
    • Resources
    • FAQ’s
  • Healthcare Professionals
    • COVID-19
    • Heart Failure
    • Critical Care
    • Other Indications
    • Clinical Evidence
    • Case Studies
    • The BVA Brief Newsletter
    • Reimbursement
    • Technical Resources
    • Clinical Support Team
  • Innovations
  • Investors
    • Tear Sheet
    • Press Releases
    • Executive Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • SEC Filings
    • FAQ’s
    • Key Contacts
  • Contact
News
23 Mar 2023

New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients

admin
News
23 Mar 2023

Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients

admin
News
03 Mar 2023

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

admin
News
02 Mar 2023

Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022

admin
News
01 Mar 2023

Daxor Corporation to Report Fiscal Year 2022 Financial Results on Wednesday, March 1, 2023 and Provide Corporate Update

admin
News
17 Feb 2023

Daxor Corporation Appoints Linda Cooper, Vice President Project Management

admin
News
19 Jan 2023

Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member

admin
News
13 Jan 2023

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress

admin
News
03 Jan 2023

Newly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure

admin
News
17 Nov 2022

Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option

admin
Previous